There are a few major unmet needs in the primary sclerosing cholangitis (PSC) treatment market, which include a lack of effective therapies, proven surveillance strategies, tools for early detection of malignancies, impact on quality of life (QoL), and surrogate endpoints in primary sclerosing cholangitis clinical trials.
Although a rare disease, primary sclerosing cholangitis still affects around 30,000 people in the US, 21,000 in the EU5, 9,000 in Nordic countries, and another 1,200 in Japan in 2021. As per DelveInsight’s estimates, the overall primary sclerosing cholangitis prevalence in both genders is subject to increase in the coming years and reach up to app...
